The patent expiry date for vonoprazan in India is December 2, 2030. [1]
When will generic vonoprazan be available in India?
Following the patent expiry in December 2030, generic versions of vonoprazan are expected to become available in India. [1]
What is vonoprazan used for?
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related gastrointestinal disorders. [2]
How does vonoprazan differ from proton pump inhibitors (PPIs)?
Unlike traditional proton pump inhibitors (PPIs), vonoprazan works by reversibly inhibiting the H+, K+-ATPase enzyme in gastric parietal cells. This mechanism offers a faster and more sustained suppression of gastric acid secretion. [2]
What companies are involved with vonoprazan in India?
Takeda Pharmaceuticals is the originator company for vonoprazan. [3] Information regarding other companies that may be manufacturing or distributing vonoprazan or its generics in India post-patent expiry can be tracked through patent databases and regulatory filings. DrugPatentWatch.com monitors such patent landscapes. [1]
What are the potential challenges to vonoprazan patents in India?
Patents can be subject to challenges in India, as in other jurisdictions. These challenges can be brought by competitors seeking to market generic versions of a drug. The specific patent landscape and any ongoing or potential litigation for vonoprazan in India would require detailed examination of Indian patent law and filings. [1]